3bjc: Difference between revisions

From Proteopedia
Jump to navigationJump to search
Newer edit →
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,330,058 edits
New page: left|200px <!-- The line below this paragraph, containing "STRUCTURE_3bjc", creates the "Structure Box" on the page. You may change the PDB parameter (which sets the PD...
 
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,330,058 edits
No edit summary
Line 1: Line 1:
[[Image:3bjc.jpg|left|200px]]
{{Seed}}
[[Image:3bjc.png|left|200px]]


<!--
<!--
Line 9: Line 10:
{{STRUCTURE_3bjc|  PDB=3bjc  |  SCENE=  }}  
{{STRUCTURE_3bjc|  PDB=3bjc  |  SCENE=  }}  


'''Crystal structure of the PDE5A catalytic domain in complex with a novel inhibitor'''
===Crystal structure of the PDE5A catalytic domain in complex with a novel inhibitor===




==Overview==
<!--  
Selective inhibitors of cyclic nucleotide phosphodiesterase-5 (PDE5) have been used as drugs for treatment of male erectile dysfunction and pulmonary hypertension. An insight into the pharmacophores of PDE5 inhibitors is essential for development of second generation of PDE5 inhibitors, but has not been completely illustrated. Here we report the synthesis of a new class of the sildenafil derivatives and a crystal structure of the PDE5 catalytic domain in complex with 5-(2-ethoxy-5-(sulfamoyl)-3-thienyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyra zolo[4,3-d]pyrimidin-7-one (12). Inhibitor 12 induces conformational change of the H-loop (residues 660-683), which is different from any of the known PDE5 structures. The pyrazolopyrimidinone groups of 12 and sildenafil are well superimposed, but their sulfonamide groups show a positional difference of as much as 1.5A. The structure-activity analysis suggests that a small hydrophobic pocket and the H-loop of PDE5 are important for the inhibitor affinity, in addition to two common elements for binding of almost all the PDE inhibitors: the stack against the phenylalanine and the hydrogen bond with the invariant glutamine. However, the PDE5-12 structure does not provide a full explanation to affinity changes of the inhibitors. Thus alternatives such as conformational change of the M-loop are open and further structural study is required.
The line below this paragraph, {{ABSTRACT_PUBMED_18346713}}, adds the Publication Abstract to the page
(as it appears on PubMed at http://www.pubmed.gov), where 18346713 is the PubMed ID number.
-->
{{ABSTRACT_PUBMED_18346713}}


==About this Structure==
==About this Structure==
Line 44: Line 48:
[[Category: Polymorphism]]
[[Category: Polymorphism]]
[[Category: Zinc]]
[[Category: Zinc]]
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Apr 30 13:32:45 2008''
 
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 29 02:42:58 2008''

Revision as of 23:43, 28 July 2008

File:3bjc.png

Template:STRUCTURE 3bjc

Crystal structure of the PDE5A catalytic domain in complex with a novel inhibitor

Template:ABSTRACT PUBMED 18346713

About this Structure

3BJC is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

Reference

An insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studies., Chen G, Wang H, Robinson H, Cai J, Wan Y, Ke H, Biochem Pharmacol. 2008 May 1;75(9):1717-28. Epub 2008 Feb 12. PMID:18346713

Page seeded by OCA on Tue Jul 29 02:42:58 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "https://proteopedia.org/index.php?title=3bjc&oldid=723567"